Recent News

• 09.17.2025 - Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
• 09.17.2025 - Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
• 09.15.2025 - Stifel 2025 Virtual Immunology and Inflammation Forum
• 09.12.2025 - Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
• 09.12.2025 - Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
• 09.09.2025 - Baird 2025 Global Healthcare Conference
• 09.02.2025 - Sarah Reed
• 09.02.2025 - Sarah Reed
• 09.02.2025 - Citi's 2025 Biopharma Back to School Conference
• 09.02.2025 - Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Recent Filings

• 09.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.12.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 09.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.09.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 09.08.2025 - 3 Initial statement of beneficial ownership of securities
• 09.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.03.2025 - 144 Report of proposed sale of securities